Approval of nivolumab followed a randomized phase III trial comparing it (at 3 mg/kg IV q2W, n = 120) to investigator's choice chemotherapy (n = 47) in MM patients refractory to CTLA-4 and/or BRAF inhibition [50]. The gene discussed is CTLA4; the disease is Miyoshi myopathy.